The participants agreed that several factors can influence the time window in which to test for CCL14, and that patients with stage 2 or 3 AKI who are candidates for CCL14 testing should be timely screened after clinical evaluation justifies assessment of risk for PS-AKI (Supplementary Table 10). Here, CCL14 is linked to acute kidney injury.